Paul Hastings LLP advised Orchestra BioMed on the deal.
Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced its business combination agreement to merge with Health Sciences Acquisitions Corporation 2 (HSAC2), a special purpose acquisition company (SPAC). The combined company is expected to have a fully diluted pro forma market cap of up to $407 million, assuming no redemptions. Upon closing of the transaction, the combined company will be named Orchestra BioMed Holdings, Inc., and its common stock will be listed on Nasdaq under the ticker symbol “OBIO.”
The Paul Hastings team was led by M&A/Emerging Growth Companies partner Sam Waxman (Picture), and included partners Yariv Katz, Lucas Rachuba, and Todd Schneider; of counsels Keith Pisani and Amy Lawrence; and associates Jordan Goldman, Vinnie Buehler, Anna Hardcastle, Tianzi Wu, Nicolette Ursini and Shai Marshall.
Involved fees earner: Vinnie Buehler – Paul Hastings LLP; Jordan Goldman – Paul Hastings LLP; Anna Hardcastle – Paul Hastings LLP; Yariv Katz – Paul Hastings LLP; Amy Lawrence – Paul Hastings LLP; Shai Marshall – Paul Hastings LLP; Keith Pisani – Paul Hastings LLP; Todd Schneider – Paul Hastings LLP; Nicolette Ursini – Paul Hastings LLP; Samuel Waxman – Paul Hastings LLP;
Law Firms: Paul Hastings LLP;
Clients: Orchestra BioMed;